Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(1.00) by 70.97 percent. This is a 61.33 percent increase over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $47.955 million. This is a 1.19K percent increase over sales of $3.708 million the same period last year.